The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Trends Update — Comparative Effectiveness: Where Data Shows No Difference, Tie Should Go To the Patient

A post by Scott Hensley on the NPR Health Blog yesterday has some good food for thought in the comparative effectiveness debate: what to do when comparative effectiveness studies show no statistically significant difference between treatments.

The post notes that insurance coverage will be a factor in these decisions, but that:

“in the end, it might be you and your gut feeling.”

In one of this blog’s prior posts, I noted that it will be hard to distinguish between treatments that show different effectiveness because of personal differences between patients and those that would show different results even if the patients were identical. 

Hensley’s post illustrates that no matter how much data we gather, there will be gray areas where doctors and patients have to make subjective calls.  I hope payors will be extremely cautious about second-guessing these decisions.  Tie goes to the patient.

Bookmark and Share

About these ads

One response to “Trends Update — Comparative Effectiveness: Where Data Shows No Difference, Tie Should Go To the Patient

  1. Pingback: Comparative Effectiveness and Personalized Medicine are “Part of the Same Question” Collins Confirms « The Cross-Border Biotech Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 126 other followers